Moreover, the progressive dose reduction (from 100 mg to 80 mg, and later to 50 mg/day) may have attenuated PDGFR inhibition, allowing for a partial restoration of bone homeostasis while maintaining molecular control of leukemia. The gene discussed is PDGFRB; the disease is leukemia.